parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in oligodendrocytes (61 nCPM)	1.00
chemistry Open Targets	a small-molecule pocket	0.50
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 11890

PDCD6 in dopamine neurons, braak-0.17 (p 0.663) → +0.38 (p 0.311)receipt 11898
PDCD6 in oligodendrocytes, braak+0.22 (p 0.565) → +0.21 (p 0.586)receipt 11897

receipt 11898: PDCD6 in dopamine neurons, braak

power: full sample +0.11 (p 0.664, n 18), 95% CI -0.38 to +0.55. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.08 (p 0.754, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.08 (p 0.754, n 18). could be the mix.
skeptic: leave-one-out range +0.00 to +0.24, sign flips 2; without severely affected donors +0.11 (p 0.664, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PDCD6 in dopamine neurons.

case closed: nothing better to follow up.

receipt 11897: PDCD6 in oligodendrocytes, braak

power: full sample +0.29 (p 0.246, n 18), 95% CI -0.21 to +0.67. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.27 (p 0.285, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.30 (p 0.221, n 18). could be the mix.
skeptic: leave-one-out range +0.19 to +0.48, sign flips 0; without severely affected donors +0.29 (p 0.246, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PDCD6 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts